Study guide
15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management
Key Takeaways Explain This Topic AI
Malignant Hyperthermia (MH) is an autosomal dominant pharmacogenetic myopathy caused primarily by mutations in the ryanodine receptor gene (RYR1), triggered by ALL halogenated volatile anesthetics and the depolarizing muscle relaxant succinylcholine.
The earliest and most sensitive clinical signs of MH are unexplained sudden tachycardia and an refractory surge in End-Tidal CO₂ (ETCO₂ > 60-80 mmHg) despite hyperventilation, plus masseter muscle rigidity (MMR); hyperthermia (>41°C) is a late sign accompanied by mixed metabolic/respiratory acidosis, hyperkalemia, and rhabdomyolysis.
Immediate MHAUS protocol: Call for help/MH cart, discontinue triggers, hyperventilate with 100% O₂ at ≥10 L/min, and administer Dantrolene sodium 2.5 mg/kg IV push repeated every 5-10 minutes up to 10 mg/kg (or Ryanodex 250 mg/vial in 5 mL sterile water).
Calcium Channel Blockers (e.g., Verapamil, Diltiazem) are strictly CONTRAINDICATED during an MH crisis treated with dantrolene due to the risk of fatal hyperkalemia and profound cardiovascular collapse.
Airway fire protocol mandates immediate 4-step sequence: (1) Pull endotracheal tube, (2) Stop all airway gas flows, (3) Pour sterile saline/water into airway, and (4) Mask ventilate with room air/low FiO₂ and evaluate airway with bronchoscopy.
Last updated: August 2026
15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management
Malignant Hyperthermia (MH) is a life-threatening, hypermetabolic pharmacogenetic crisis of skeletal muscle triggered by exposure to volatile inhalational anesthetics and succinylcholine. Without immediate diagnosis and targeted intervention with Dantrolene sodium, mortality exceeds 70 − 80 % 70 - 80\% 70 − 80% ; with modern protocols, mortality is reduced to < 5 % <5\% < 5% .
1. Pathophysiology & Genetic Basis of MH [MALIGNANT HYPERTHERMIA PATHOPHYSIOLOGY]
- [Trigger: Halogenated Volatiles / Succinylcholine]
- |
- v
- [Mutated RYR1 / Cav1.1 (DHP) Receptor Activation]
- |
- v
- >>> UNCONTROLLED CALCIUM EFFLUX FROM SARCOPLASMIC RETICULUM <<<
- |
- v
- [Intracellular Free Ca²⁺ Concentration Rises 5- to 10-Fold in Myoplasm]
- |
- +-------------------+-------------------+
- | |
- v v
- [Sustained Muscle Contraction] [Massive ATP Depletion &
- (Rigor, Masseter Spasm, Rigidity) Hypermetabolic State]
- | |
- +-------------------+-------------------+
- |
- v
- [Uncoupled Oxidative Phosphorylation & Glycolysis Surge]
- |
- Extreme CO₂ Production (ETCO₂ > 80 mmHg) & O₂ Consumption
- Severe Combined Metabolic (Lactic) & Respiratory Acidosis
- Massive Heat Production (Hyperthermia > 41-43°C)
- |
- v
- [Sarcolemmal Breakdown & Rhabdomyolysis]
- Hyperkalemia (K⁺ > 6-8 mEq/L) ---> Lethal Ventricular Arrhythmias
- Myoglobinuria (Cola Urine) ---> Acute Renal Tubular Failure
- Creatine Kinase (CK) Surge ---> > 20,000 - 100,000+ U/L
- Genetics & Associated Musculoskeletal Disorders
Inheritance: Autosomal dominant with variable penetrance and expressivity.
Primary Gene Mutation: R Y R 1 RYR1 R Y R 1 gene on chromosome 19q13.1 (encodes the skeletal muscle Ryanodine Receptor Type 1 calcium-release channel; accounts for > 70 − 80 % >70 - 80\% > 70 − 80% of cases). Other implicated mutations include C A C N A 1 S CACNA1S C A CN A 1 S (dihydropyridine receptor α 1 \alpha_1 α 1 -subunit) and S T A C 3 STAC3 ST A C 3 .
Conclusively Associated Diseases:
Central Core Disease (strongly linked to R Y R 1 RYR1 R Y R 1 mutations).
King-Denborough Syndrome (dysmorphic features, myopathy, high MH risk).
Multiminicore Disease .
Critical NBCRNA Distinction on Muscular Dystrophies: Duchenne and Becker muscular dystrophies are NOT classic Malignant Hyperthermia susceptibilities. However, administration of succinylcholine or volatile agents to patients with Duchenne/Becker dystrophy can trigger Anesthesia-Induced Rhabdomyolysis (AIR) , causing sudden catastrophic hyperkalemic cardiac arrest. Succinylcholine is strictly contraindicated in all muscular dystrophies.
Triggering vs. Safe Agents +---------------------------------------------------------------------------------------------------------+
- | MH PHARMACOLOGIC AGENT CLASSIFICATION |
- +------------------------------------+--------------------------------------------------------------------+
- | Class Category | Specific Pharmacologic Agents |
- +------------------------------------+--------------------------------------------------------------------+
- | **KNOWN TRIGGERS** | • **ALL Halogenated Volatile Gases:** Sevoflurane, Desflurane, |
- | *(Strictly Contraindicated)* | Isoflurane, Halothane, Enflurane |
- | | • **Depolarizing NMBA:** Succinylcholine |
- +------------------------------------+--------------------------------------------------------------------+
- | **SAFE ANESTHETIC AGENTS** | • **IV Hypnotics:** Propofol, Etomidate, Ketamine, Barbiturates |
- | *(Non-Triggering)* | • **Inhaled Non-Volatile:** Nitrous Oxide (N₂O) |
- | | • **Nondepolarizing NMBAs:** Rocuronium, Vecuronium, Cisatracurium |
- | | • **Reversal Agents:** Sugammadex, Neostigmine, Glycopyrrolate |
- | | • **Opioids & Sedatives:** Fentanyl, Morphine, Remifentanil, Midazolam|
- | | • **Local Anesthetics:** ALL amides (Lidocaine, Bupivacaine, Ropi) |
- | | and ALL esters (Tetracaine, Chloroprocaine) |
- +------------------------------------+--------------------------------------------------------------------+
2. Clinical Presentation: Early vs Late Signs +---------------------------------------------------------------------------------------------------------+
- | MH CLINICAL PROGRESSION PHASES |
- +------------------+--------------------------------------------------+-----------------------------------+
- | Clinical Phase | Key Signs & Symptoms | Diagnostic & Clinical Significance|
- +------------------+--------------------------------------------------+-----------------------------------+
- | **Earliest & | • **Unexplained Sudden Tachycardia** | • Earliest clinical sign |
- | Most Sensitive | • **Profound Surge in ETCO₂ (>60-80 mmHg)** | • Refractory to doubling or |
- | Signs** | unresponsive to hyperventilation | tripling minute ventilation |
- | | • **Masseter Muscle Rigidity (MMR)** | • "Jaws of steel" post-succinyl- |
- | | • Tachypnea & Tachypnea-induced Exhaustion | choline prevents laryngoscopy |
- +------------------+--------------------------------------------------+-----------------------------------+
- | **Intermediate | • Generalized skeletal muscle rigidity (rigor) | • Occurs despite full chemical |
- | Signs** | • Combined respiratory & metabolic acidosis | neuromuscular blockade |
- | | • Skin mottling, sweating, and cyanosis | • Mixed venous PO₂ drops near 0 |
- | | • Cardiac arrhythmias (PVCs, ventricular tach) | • Sympathetic overactivity |
- +------------------+--------------------------------------------------+-----------------------------------+
- | **Late Signs** | • **Severe Rapid Hyperthermia (>41°C / 106°F)** | • Core temp rises >1°C q5min |
- | *(Indicates | • Hyperkalemia (K⁺ > 6 - 8 mEq/L) | • Peaked T waves, sine waves, VF |
- | Severe Muscle | • Myoglobinuria (tea- or cola-colored urine) | • Acute tubular necrosis / AKI |
- | Necrosis)* | • Marked Creatine Kinase elevation (>20,000 U/L) | • Peaking at 12-24 hours post-MH |
- | | • Disseminated Intravascular Coagulation (DIC) | • Diffuse microvascular bleeding |
- +------------------+--------------------------------------------------+-----------------------------------+
- 3. MHAUS Emergency Treatment Protocol (Step-by-Step)
Upon suspecting an MH crisis, activate the standardized Malignant Hyperthermia Association of the United States (MHAUS) protocol immediately: +---------------------------------------------------------------------------------------------------------+
- | MHAUS EMERGENCY CRISIS MANAGEMENT PROTOCOL |
- +------+-----------------------------+--------------------------------------------------------------------+
- | Step | Action Item | Protocol Execution Details |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **1**| **Call for Help & MH Cart** | • Declare MH emergency; notify surgical team to halt procedure |
- | | | • Call MHAUS 24/7 Crisis Hotline: **1-800-644-9737 (1-800-MH-HYPER)**|
- +------+-----------------------------+--------------------------------------------------------------------+
- | **2**| **Discontinue Triggers** | • Shut off volatile vaporizers and halt succinylcholine |
- | | | • Do NOT waste time changing anesthesia machine or circuit |
- | | | • Insert activated charcoal filters (Vapor-Clean) on limbs |
- | | | • Switch to TIVA (Propofol / Opioids) |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **3**| **Hyperventilate 100% O₂** | • Flush circuit with 100% O₂ at maximum fresh gas flows (≥10 L/min)|
- | | | • Hyperventilate at 2 to 3 times normal minute ventilation to |
- | | | blow off massive CO₂ production |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **4**| **Administer Dantrolene** | • **Initial Dose: 2.5 mg/kg IV push immediately** |
- | | | • Repeat 1 - 2.5 mg/kg every 5-10 minutes until signs subside |
- | | | • Cumulative dose may exceed **10 mg/kg** in severe crises |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **5**| **Treat Acidosis** | • Administer Sodium Bicarbonate 1 - 2 mEq/kg IV guided by ABG |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **6**| **Treat Hyperkalemia** | • **Calcium Chloride 10 mg/kg (or 1 g)** or Calcium Gluconate 3 g |
- | | | IV to stabilize cardiac membranes |
- | | | • **Regular Insulin 10 units IV + D50W 50 mL (25 g)** |
- | | | • Sodium Bicarbonate + Hyperventilation + Albuterol |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **7**| **Treat Arrhythmias** | • Use Amiodarone (150-300 mg), Lidocaine, or Beta-blockers |
- | | | • **STRICTLY AVOID CALCIUM CHANNEL BLOCKERS (Verapamil/Diltiazem)**|
- +------+-----------------------------+--------------------------------------------------------------------+
- | **8**| **Initiate Active Cooling** | • Infuse cold 0.9% Normal Saline IV (1000 mL q10min x 30-40 min) |
- | | | • Ice packs to groin, axillae, neck; gastric/bladder cold lavage |
- | | | • **STOP COOLING AT 38.5°C** to prevent rebound hypothermia |
- +------+-----------------------------+--------------------------------------------------------------------+
- | **9**| **Maintain Renal Output** | • Target Urine Output **≥ 1 - 2 mL/kg/hr** to flush myoglobin |
- | | | • Administer IV crystalloid fluids, Mannitol 0.25 g/kg, Lasix |
- +------+-----------------------------+--------------------------------------------------------------------+
- |**10**| **ICU Monitoring & Recrud.**| • Transfer to ICU for continuous hemodynamic and lab monitoring |
- | | | • **Recrudescence occurs in ~20% of cases within 24 - 36 hours** |
- | | | • Maintenance Dantrolene: 1 mg/kg IV q4-6h or 0.25 mg/kg/hr for 24h|
- +------+-----------------------------+--------------------------------------------------------------------+
- Dantrolene Sodium: Formulations & Pharmacology
Mechanism of Action: Dantrolene binds specifically to the ryanodine receptor 1 ( R Y R 1 RYR1 R Y R 1 ) channel , blocking intracellular calcium release from the sarcoplasmic reticulum into the myoplasm, halting uncoupled muscle contraction and metabolic runaway.
Formulations Comparison:
Ryanodex (Nanocrystalline Suspension): Each vial contains 250 mg 250 \text{ mg} 250 mg dantrolene sodium + 125 mg 125 \text{ mg} 125 mg mannitol. Reconstitutes with only 5 mL 5 \text{ mL} 5 mL sterile water in < 10 seconds <10 \text{ seconds} < 10 seconds . A single vial provides the entire loading dose for a 100 kg 100 \text{ kg} 100 kg patient.
Revonto / Dantrium (Lyophilized Formulation): Each vial contains 20 mg 20 \text{ mg} 20 mg dantrolene sodium + 3000 mg 3000 \text{ mg} 3000 mg ( 3 g 3 \text{ g} 3 g ) mannitol + sodium hydroxide. Requires 60 mL 60 \text{ mL} 60 mL sterile water per vial and vigorous shaking. A 70 kg 70 \text{ kg} 70 kg patient requires ≈ 9 \approx 9 ≈ 9 vials for initial loading ( 180 mg 180 \text{ mg} 180 mg ); a 100 kg 100 \text{ kg} 100 kg patient at 10 mg/kg 10 \text{ mg/kg} 10 mg/kg requires 50 vials 50 \text{ vials} 50 vials and 3 Liters 3 \text{ Liters} 3 Liters of sterile water .
The Calcium Channel Blocker Lethal Trap
Administering calcium channel blockers (such as Verapamil or Diltiazem) in the presence of Dantrolene is strictly contraindicated. The combination produces profound hyperkalemia, myocardial contractility depression, and refractory lethal cardiovascular collapse .
Definitive Diagnosis: Caffeine-Halothane Contracture Test (CHCT)
Gold Standard: In vitro muscle contracture testing of a freshly biopsied vastus lateralis muscle exposed to caffeine and halothane solutions. Abnormal contracture confirms MH susceptibility. Performed only at specialized testing centers.
Genetic Screening: Sequence analysis of R Y R 1 RYR1 R Y R 1 and C A C N A 1 S CACNA1S C A CN A 1 S mutations. A positive genetic test confirms susceptibility, but a negative genetic test does not rule out MH due to undiscovered mutations.
4. Operating Room Airway Fire Crisis Protocol
Airway fires represent one of the most catastrophic emergencies in head, neck, and ENT anesthesia. Combustion requires the Surgical Fire Triad :
Fuel: Endotracheal tube, tracheal drapes, alcohol prep, sponges.
Oxidizer: Oxygen ( F i O 2 > 0.30 FiO_2 > 0.30 F i O 2 > 0.30 ), Nitrous Oxide ( N 2 O N_2O N 2 O supports combustion equally with oxygen).
Ignition Source: Electrosurgical unit (bovie), laser (CO₂, Nd:YAG), electrocautery. [EMERGENCY AIRWAY FIRE 4-STEP SEQUENCE]
- STEP 1: PULL THE ENDOTRACHEAL TUBE IMMEDIATELY
- (Remove burning foreign body from patient's airway)
- |
- v
- STEP 2: STOP ALL AIRWAY GAS FLOWS
- (Turn off O₂ and N₂O; disconnect breathing circuit)
- |
- v
- STEP 3: EXTINGUISH WITH STERILE SALINE / WATER
- (Pour sterile saline/water directly into airway and pharynx)
- |
- v
- STEP 4: VENTILATE WITH ROOM AIR & EVALUATE AIRWAY
- Mask ventilate with 100% room air (or minimum FiO₂ needed)
- Perform rigid / flexible bronchoscopy to assess mucosal damage
- Re-intubate with smaller tube or perform emergency tracheostomy